Jürgen Schölmerich, Klaus Fellermann, Frank W. Seibold, Gerhard Rogler, Jost Langhorst, Stefanie Howaldt, Gottfried Novacek, Andreas Munk Petersen, Oliver Bachmann, Harald Matthes, Norbert Hesselbarth, Niels Teich, Jan Wehkamp, Jochen Klaus, Claudia Ott, Karin Dilger, Roland Greinwald, Ralph Mueller
- BACKGROUND AND AIMS To investigate the efficacy and safety of three different dosages of embryonated, viable eggs of Trichuris suis [TSO] versus placebo for induction of remission in mildly-to-moderately active ileocolonic, uncomplicated Crohn's disease [CD].
METHODS Adults with active CD [n = 252] randomly received six fortnightly doses of 250, 2500, or 7500 TSO/15 ml suspension/day [TSO 250, TSO 2500, TSO 7500], or 15 ml placebo solution/day, in a double-blind fashion, with 4 weeks' follow-up. Primary endpoint was the rate of clinical remission [Crohn's Disease Activity Index [CDAI] < 150] at end of treatment, ie at Week 12 or withdrawal. Secondary endpoints included the course of clinical remission, rate of clinical response, change in CDAI, change in markers of inflammation, mucosal healing, and Physician's Global Assessment.
RESULTS Clinical remission at Week 12 occurred in 38.5%, 35.2%, and 47.2% of TSO 250, TSO 2500, and TSO 7500 patients, respectively, and in 42.9% of placebo recipients. TSO induced a dose-dependent immunological response. There was no response regarding laboratory markers of inflammation. Other secondary efficacy variables also showed no advantage of TSO over placebo for treatment of active CD. Administration of TSO did not result in any serious adverse drug reaction. Review of non-serious suspected adverse drug reactions following TSO did not reveal any safety concerns.
CONCLUSIONS Administration of 250-7500 TSO fortnightly over 12 weeks was safe and showed a dose-dependent immunological response, but no TSO dose showed a clinically relevant effect over placebo for induction of clinical remission or response in mildly-to-moderately active, ileocolonic CD.
MetadatenAuthor: | Jürgen Schölmerich, Klaus Fellermann, Frank W. Seibold, Gerhard Rogler, Jost Langhorst, Stefanie Howaldt, Gottfried Novacek, Andreas Munk Petersen, Oliver Bachmann, Harald Matthes, Norbert HesselbarthORCiDGND, Niels Teich, Jan Wehkamp, Jochen Klaus, Claudia Ott, Karin Dilger, Roland Greinwald, Ralph Mueller |
---|
URN: | urn:nbn:de:hebis:30:3-439270 |
---|
DOI: | https://doi.org/10.1093/ecco-jcc/jjw184 |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/27707789 |
---|
Parent Title (English): | Journal of Crohn's colitis |
---|
Document Type: | Article |
---|
Language: | English |
---|
Year of Completion: | 2017 |
---|
Date of first Publication: | 2017/04/01 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Contributing Corporation: | International TRUST-2 Study Group |
---|
Release Date: | 2017/11/02 |
---|
Volume: | 11 |
---|
Issue: | 4 |
---|
First Page: | 390 |
---|
Last Page: | 399 |
---|
Note: | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
---|
HeBIS-PPN: | 427970199 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (English): | Creative Commons - Namensnennung-Nicht kommerziell 4.0 |
---|